Aktis Oncology (AKTS) vs Alto Neuroscience (ANRO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Aktis Oncology is the larger company by market cap ($1.00 billion vs $923.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AKTS | ANRO |
|---|---|---|
| Share price | $18.00 | $23.52 |
| Market cap | $1.00B | $922.97M |
| 1-day change | +0.78% | -0.72% |
| YTD return | — | +32.13% |
| 1-year return | — | +295.96% |
| EPS (TTM) | $-1.70 | $-2.31 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $34.19 | $37.48 |
| 52-week low | $14.72 | $5.23 |
| Distance from 52-week high | -47.35% | -37.25% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +96.61% | +63.18% |
| Average volume | 364.04K | 540.09K |
| Shares outstanding | 53.75M | 39.24M |
| Employees | 79 | 68 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Aktis Oncology
AKTS stock →Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and [225Ac]Ac-AKY-2519 to deliver 225Ac to B7-H3 (CD276) expressing tumors, including prostate, lung and other solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 79 employees
About Alto Neuroscience
ANRO stock →Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 68 employees
AKTS vs ANRO FAQ
Which is bigger, Aktis Oncology or Alto Neuroscience?
Aktis Oncology (AKTS) is larger, with a market capitalization of $1.00B compared with $922.97M for Alto Neuroscience (ANRO).
Are Aktis Oncology and Alto Neuroscience in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.